| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 8.14 | 0.06 (+0.74%) | 6.92 - 17.48 | 711.3 thousand (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 8.09 |
|---|---|
| Previous Close | 8.08 |
| Day's Range | 8.03 - 8.18 |
| Market Cap | 488.6M |
| Avg Volume (10 Day) | 1.0M |
| Price/Earnings (Trailing 12 Mo.) | 11.5x |
| Earnings Per Share (Trailing 12 Mo.) | 0.71 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Spectrum Pharmaceuticals to Present Corporate Update at the UBS Global Healthcare Conference in New York City on May 20th
Business Wire - Monday 05/13/2013 7:00 AM ET
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 14th
Business Wire - Friday 05/10/2013 7:00 AM ET
Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013
Business Wire - Thursday 05/09/2013 7:00 AM ET
Spectrum Pharmaceuticals Announces First Quarter 2013 Financial Results Teleconference and Webcast
Business Wire - Thursday 05/02/2013 7:00 AM ET
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Spectrum Pharmaceuticals, Inc. of Upcoming Deadline
Business Wire - Tuesday 04/30/2013 5:21 PM ET
Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.
Business Wire - Sunday 04/28/2013 2:00 PM ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position
Business Wire - Friday 04/26/2013 7:14 AM ET
21 Days Remain before May 13, 2013, Lead Plaintiff Deadline in Investor Lawsuit against Spectrum Pharmaceuticals, Inc.
Business Wire - Tuesday 04/23/2013 9:30 AM ET
| SPPI | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 17.82% | |
| Net Income Growth (1yr) | -45.05% | |
| Total Debt/Equity | 0.29 | |
| LT Debt/Equity | 0.29 | |
| Earnings Yield | 8.70% | |
| Price/Sales | 1.98 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 6.75 | -8.66% |
| Protalix Biotherapeutics Inc | 5.16 | -1.15% |
| Sequenom Inc | 4.10 | -0.24% |
| Sangamo BioSciences Inc | 8.43 | +2.06% |
| Emergent BioSolutions Inc | 14.56 | +0.90% |
Data is delayed by at least 15 min.